Skip to main content

Advertisement

Log in

ASO Author Reflections: Presacral Neuroendocrine Neoplasms—Insights into a Rare Disease

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hobson KG, Ghaemmaghami V, Roe JP, Goodnight JE, Khatri VP. Tumors of the retrorectal space. Dis Colon Rectum. 2005;48(10):1964–74.

    Article  PubMed  Google Scholar 

  2. Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, Librizzi D, Kender Z, Kröcher A, Kreutzfeldt S, Gress TM, Rinke A. Multicenter analysis of presacral neuroendocrine neoplasms-clinicopathological characterization and treatment outcomes of a rare disease. Front Endocrinol (Lausanne). 2021;12:709256. https://doi.org/10.3389/fendo.2021.709256.PMID:34690926;PMCID:PMC8527170.

    Article  PubMed  Google Scholar 

  3. Violante T, Murphy B, Ferrari D, et al. Presacral neuroendocrine neoplasms: a multi-site review of surgical outcomes. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15328-3.

    Article  PubMed  Google Scholar 

  4. Ferrari D, Violante T, Addison P, et al. Robotic resection of presacral tumors. Tech Coloproctol. (in press).

  5. Chan J, Geyer S, Ou FS, Knopp M, Behr S, Zemla T, et al. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Ann Oncol. 2023;34:S1292.

    Article  Google Scholar 

Download references

Funding

This research did not receive external funding.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William R. G. Perry MB.

Ethics declarations

Disclosure

Thorvadur Halfdanarson

Support

Thermo Fisher Scientific; Advanced Accelerator Applications (a Novartis company); Camurus; Crinetics; ITM Isotopen Technologien Muenchen; Perspective Therapeutics Consultancy/Advisory Board/Steering Committees: Exelixis; TerSera; Ipsen; Novartis; ITM Isotopen; Technologien Muenchen; Crinetics; Perspective Therapeutics; Camurus; Abdera Therapeutics

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article refers to:Violante T, Murphy B, Ferrari D, et al. Presacral neuroendocrine neoplasms: A multi-site review of surgical outcomes. Annals Surgical Oncology. (2024). https://doi.org/10.1245/s10434-024-15328-3.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Violante, T., Dozois, E.J., Halfdanarson, T.R. et al. ASO Author Reflections: Presacral Neuroendocrine Neoplasms—Insights into a Rare Disease. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15472-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1245/s10434-024-15472-w

Navigation